Salmela P I, Gordin A, Salo H, Ottoila P, Jounela A J
Department of Medicine, University Central Hospital, Oulu, Finland.
Ann Clin Res. 1988;20(3):195-200.
The antihypertensive effect of verapamil administered either two or three times daily was compared in a double blind, cross over study in 15 patients with mild to moderate essential hypertension. During the dose titration period with t.i.d. administration, normotension was obtained with daily doses of 240 mg in 7 patients, 360 mg in 7 patients and with 480 mg in one patient. Systolic and diastolic blood pressures (BP) in the supine (13/14 mmHg) and standing (14/14 mmHg) positions were significantly (p less than 0.001) reduced during the dose titration period. There was no statistically significant difference in the BP values between the twice and three times a day regimens. Five to 7-fold individual variations in the serum verapamil concentrations between individuals were observed. No significant correlations were found between serum drug concentrations and the change in mean arterial BP. There was no significant difference in the incidence of side effects between the two treatment regimens. Our results suggest that verapamil administered twice daily is effective in mild to moderate hypertension.
在一项针对15例轻度至中度原发性高血压患者的双盲交叉研究中，比较了每日服用两次和三次维拉帕米的降压效果。在每日三次给药的剂量滴定期间，7例患者每日服用240mg、7例患者每日服用360mg以及1例患者每日服用480mg时血压恢复正常。在剂量滴定期间，仰卧位（收缩压和舒张压分别降低13/14mmHg）和站立位（收缩压和舒张压分别降低14/14mmHg）的收缩压和舒张压均显著降低（p<0.001）。每日两次和三次给药方案之间的血压值无统计学显著差异。个体间血清维拉帕米浓度存在5至7倍的个体差异。未发现血清药物浓度与平均动脉压变化之间存在显著相关性。两种治疗方案的副作用发生率无显著差异。我们的结果表明，每日两次服用维拉帕米对轻度至中度高血压有效。
